We would love to hear your thoughts about our site and services, please take our survey here.
And the Investigator is Dr William Tap
https://www.mskcc.org/cancer-care/doctors/william-tap
23rd February 2023
Dr. William Tap:
If we have a version of Doxorubicin (AVA6000) that works better than the current
offering then, overnight, that becomes the new standard of care.
GLA
Sorry, typo on Cohort numbers:
- Cohort I was 80mg/m2
- Cohort II was 120mg/m2
- Cohort III was 160mg/m2
- Cohort IV was 200mg/m2.
- Cohort V is 250mg/m2.
I was expecting Cohort V at 240mg/m2. 250mg/m2 is an increase but not a major increase, (300mg/m2).
Can someone explain the science behind the Cohort V dosage?
Thank you
- Cohort III was 80mg/m2
- Cohort III was 120mg/m2
- Cohort III was 160mg/m2
- Cohort IV was 200mg/m2.
- Cohort V is 250mg/m2.
I was expecting Cohort V at 240mg/m2. 250mg/m2 is an increase but not a major increase, (300mg/m2).
Can someone explain the science behind the Cohort V dosage?
Thank you
Bottom of the page: https://avacta.com/investors/ceo-welcome/
AVA6000 with Doxorubicin
Doxorubicin, sold under the brand name Adriamycin among others, is a chemotherapy medication used to treat cancer. This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukaemia.
AVA3996 with Bortezomib
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. This includes multiple myeloma in those who have and have not previously received treatment.
Avacta’s AVA6000 and AVA3996 have the potential to deliver treatments directly to the tumour microenvironment while reducing systemic exposures. Avacta is developing multiple solutions to improve the delivery and effectiveness of existing, proven cancer treatments.
Setting aside the commercial opportunities, isn’t this fantastic news for those requiring treatment(s).
GLA
What Do We Know:
Avacta is funded (approximately £ 64m) in to 2024 and beyond.
https://avacta.com/result-of-the-open-offer/
Avacta has a very strong Scientific Team and is strengthening the Commercial & Legal.
https://avacta.com/careers/careervacancies/
LG Chem has renewed their Affimer licence triggering payments to Avacta
https://avacta.com/lg-chem-renews-license-triggering-payment-to-avacta/
FDA has granted Orphan Status to AVA6000.
https://avacta.com/ava6000-receives-orphan-drug-designation-from-the-us-food-and-drug-administration/
AVA6000 has successfully completed Cohort IV.
https://avacta.com/avacta-announces-successful-completion-of-fourth-dose-escalation-in-ava6000-phase-1-clinical-study/
UK Government and US FDA wish to accelerate approval of improved Oncology treatments.
FDA Issued Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval.
https://www.fda.gov/news-events/press-announcements/fda-issues-draft-guidance-aimed-improving-oncology-clinical-trials-accelerated-approval
If we have a version of Doxorubicin (AVA6000) that works better than the current
offering then, overnight, that becomes the new standard of care,
(Dr William Tap, 23rd February 2023).
AVA3996 will be presented at AACR 0n 16th April 2023.
https://avacta.com/avacta-to-present-pre-clinical-data-on-ava3996-at-the-american-association-for-cancer-research-annual-meeting/
What Don’t We Know:
- Status of AVA6000 Cohort V & VI or Phase 1B?
- Is Avacta discussing shorter routes to market (FDA) for AVA6000?
- Is Avacta discussing provisional agreements for AVA6000 with Big Pharma?
- Is a Big Pharma(s) considering Avacta and it’s IP as an acquisition target?
- What would Big Pharma value Avacta and the IP at?
Conclusion:
We have been invested for 10 years and have witnessed the share price highs and lows.
The current Market Cap is below £ 300m.
We expect 2023 to be a very significant year for Avacta, the science, the patients and the shareholders.
Some will agree, some will disagree.
We remain invested.
GLA
According to LSE, volumes bought and sold today were very similar but Avacta is down another 5%.
£1.85 to £1.12 (down 40%) in the past few weeks.
AS is holding 430,000 shares so he is personally down £ 314K over the same period. If the CEO does not have confidence in the science, and the multiple opportunities, why did he not sell and pocket £800K? Perhaps anticipating a large increase in share price?
Painful to see the current share price but there are so much opportunities. Take some time out and wait for the financials in early April followed by AACR 14-19 April 2023.
Positive News Soon?
GLA
According to Ceres Investors page: https://www.ceres.tech/investors/
Revenue: £ 32m
Cash, cash equivalents and investments = £ 250m
Ceres may not be profitable but has reserves and several partners large partners.
Interesting updates in the coming weeks and months.
GLA
Varian is an established player in the market with revenue (£ 3Bn) and profits.
AVO is new but has a unique method (LIGHT) of delivering Proton Therapy.
£ 20m Market Cap does not reflect the years and £ millions that have gone in to developing LIGHT.
Hopefully we will have positive news relating to business plan, orders and revenue soon.
As agreed, £ 20m is a bargain for the IP but we would rather see LIGHT come to market.
@Hurst - good Spot
https://www.fda.gov/about-fda/fda-organization/peter-marks
IF you had purchased 50,000 Avacta shares 3 years ago at £ 1.00 = £ 50K
BUT sold at the Covid high of £ 2.85 = £ 142.5K
MAYBE reinvested when the shares fell below £ 0.50,
you would now be holding 285,000 shares with a value at £ 1.22 = £ 347.7K
Alternatively
IF AVA6000 can successfully deliver Doxorubicin in increased doses.
BUT there are minimal side effects.
MAYBE Avacta Market Cap’ will reach £ 2Bn with a share price at £ 7.50.
The initial 50,000 Avacta shares will be valued at £ 375K.
For those that have a crystal ball, forecast the market.
Buy the troughs and sell the peaks if you can.
Risky Business.
For those that have confidence in Avacta, the science and the many offerings,
hold your investment and wait for the anticipated success and returns.
If, But, Maybe, …
GLA
The last significant RNS was the successful completion of Cohort 4.
https://avacta.com/avacta-announces-successful-completion-of-fourth-dose-escalation-in-ava6000-phase-1-clinical-study/
It has been 8 weeks since the Cohort 4 RNS (17th January 2023) so there will be other things ongoing.
Sunday evening, lets see what the week ahead brings:
- Successful completion of Cohort 5?
- Phase 1B has started?
- A Real-Time Oncology Review, (suggested by Energyshares)?
- A provisional licence deal has been signed for AVA6000?
- An update on AVA3996?
- An unsolicited bid from a big pharma?
There is so much going on and so much pending.
What next from Avacta and when?
GLA
The last significant RNS was the successful completion of Cohort 4.
https://avacta.com/avacta-announces-successful-completion-of-fourth-dose-escalation-in-ava6000-phase-1-clinical-study/
It has been 8 weeks since the Cohort 4 RNS (17th January 2023) so there will be other things ongoing.
What might the next RNS be:
- Successful completion of Cohort 5?
- Phase 1B has started?
- A Real-Time Oncology Review, (suggested by Energyshares)?
- A provisional licence deal has been signed for AVA6000?
- An update on AVA3996?
- An unsolicited bid from a big pharma?
There is so much going on and so much pending.
What next from Avacta and when?
GLA
1973
Doxorubicin (Dox’) becomes a new standard for chemotherapy treatments but has serious side effects.
2023
50 years later Dox’ remains one of the best available treatments.
Many, including BIG PHARMA's, have tried to improve treatments but have failed.
23rd February 2023
Dr. William Tap:
If we have a version of Doxorubicin (AVA6000) that works better than the current
offering then, overnight, that becomes the new standard of care.
Avacta
It has taken 50 years but Avacta may have that SPECIAL VERSION/OFFERING.
There will be additional RNS(s) updates relating to the next Cohorts, Phase 1B and,
perhaps, an offer from one of the BIG PHARMA’s.
Not too worried about the current share trades and price.
It has been 50 years. We can wait a few more weeks / months.
Wait for the inevitable BIG NEWS.
GLA
Very positive science day and data.
4.6m shares traded yesterday.
2m+ traded by 9am this morning.
February share price down from £ 1.85 to £ 1.35, (-27%).
Market cap down to £360m.
Bargain opportunity for BIG PHARMA.
Sit tight LTH’s. Something is coming.
Don’t panic sell.
GLA